University of Southern California — Biomedical Watch V2

Traitements15programmes

Essais6liés

Publications4liées

SourceDBlocale

Traitements

15

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
A Study of Brain Aging in Vietnam War VeteransTraumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer's disease (AD). The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of AD on Veterans as they age. The information collected will help to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.	Alzheimer	À vérifier	Traitement symptomatique	United States	À vérifier
Allopregnanolone injection (intravenous solution)The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose.	Alzheimer	Phase 1	À vérifier	United States	À vérifier
AmyvidThe Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
BP-REACH — Reducing Blood Pressure in Patients With High Cardiovascular RiskBP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system. The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are: * Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care? * Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?	Hypertension	Non applicable	À vérifier	United States	À vérifier
MK-6240The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
NAV4694The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
NeuraceqThe Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
PI-2620The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
T2:C100This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximately 120 participants of any gender at least 40 years of age who are hospice care-eligible with agitation and dementia (HAD). Participants will be randomized (50:50) to either active study drug (T2:C100) or placebo. The double-blind period of this study is 12 weeks. A 12 week optional open-label extension will be offered to participants who complete the double-blind period.	Alzheimer	Phase 2	À vérifier	United States	À vérifier
TauvidThe Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
Allopregnanolone injection (intravenous solution)The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose.	Alzheimer	Phase 1	À vérifier	United States	À vérifier
A Study of Brain Aging in Vietnam War VeteransTraumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer's disease (AD). The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of AD on Veterans as they age. The information collected will help to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.	Alzheimer	À vérifier	Traitement symptomatique	United States	À vérifier
NeuraceqThe Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline. ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.	Alzheimer	À vérifier	Ralentissement de la progression	United States, Canada	À vérifier
T2:C100This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximately 120 participants of any gender at least 40 years of age who are hospice care-eligible with agitation and dementia (HAD). Participants will be randomized (50:50) to either active study drug (T2:C100) or placebo. The double-blind period of this study is 12 weeks. A 12 week optional open-label extension will be offered to participants who complete the double-blind period.	Alzheimer	Phase 2	À vérifier	United States	À vérifier
BP-REACH — Reducing Blood Pressure in Patients With High Cardiovascular RiskBP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system. The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are: * Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care? * Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?	Hypertension	Non applicable	À vérifier	United States	À vérifier

Essais cliniques

6

Molécule	Indication / population	Phase	NCT	Titre	Statut
BP-REACH — Reducing Blood Pressure in Patients With High Cardiovascular Risk	Hypertension	Non applicable	NCT05937685	BP-REACH — Reducing Blood Pressure in Patients With High Cardiovascular Risk	ACTIVE_NOT_RECRUITING
T2:C100	Alzheimer	Phase 2	NCT05644262	LiBBY — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol	COMPLETED
Neuraceq	Alzheimer	À vérifier	NCT05617014	ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4	ENROLLING_BY_INVITATION
Ofatumumab	SEP	À vérifier	NCT05171972	Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment	COMPLETED
A Study of Brain Aging in Vietnam War Veterans	Alzheimer	À vérifier	NCT01687153	A Study of Brain Aging in Vietnam War Veterans	COMPLETED
Allopregnanolone injection (intravenous solution)	Alzheimer	Phase 1	NCT02221622	Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD	COMPLETED

Publications

4

Molécule	Indication / population	Titre	Journal	Date
A Study of Brain Aging in Vietnam War Veterans		Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.	The Lancet. Neurology
A Study of Brain Aging in Vietnam War Veterans		Associations Between Neurological Diseases and Dioxin Exposure Originating from Agent Orange in Vietnam: A Narrative Review.	Toxics
A Study of Brain Aging in Vietnam War Veterans		Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.	JAMA neurology
Allopregnanolone injection (intravenous solution)		Minaxolone: an evaluation with and without premedication.	Anaesthesia